1
|
Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Nishio M, Kato T, Takahashi T, Ebi H, Aono M, Yamamoto N, Ohe Y, Nakagawa K. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM. ESMO Open 2024; 9:102975. [PMID: 38520847 PMCID: PMC10980953 DOI: 10.1016/j.esmoop.2024.102975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 12/14/2023] [Accepted: 02/29/2024] [Indexed: 03/25/2024] Open
Abstract
BACKGROUND Efficacy of necitumumab [recombinant human monoclonal antibody that blocks the ligand binding epidermal growth factor receptor (EGFR)] in patients with squamous (SQ) non-small-cell lung cancer (NSCLC) has been confirmed in two randomized clinical trials (SQUIRE and JFCM). This study evaluated the association between efficacy and initial skin toxicity with necitumumab treatment by analyzing pooled data from two clinical trials (SQUIRE and JFCM). MATERIALS AND METHODS Data of 635 patients with SQ-NSCLC (intent-to-treat population) treated with necitumumab plus gemcitabine and cisplatin (N + GC) were pooled from two clinical trials (SQUIRE and JFCM). The relationship between skin toxicities developed by the end of the second cycle and efficacy was evaluated. Efficacy endpoints included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Univariate and multivariate analyses were carried out for these endpoints. RESULTS OS and ORR were associated with skin toxicity, whereas PFS was not. Patients with grade ≥2 or grade 1 skin toxicity had significantly longer OS compared to patients without skin toxicity (grade 0) in the N + GC group [median = 15.0 (grade ≥2); 12.7 (grade 1); 9.4 (grade 0) months; hazard ratio (HR) = 0.51 (grade ≥2 to grade 0); 95% confidence interval (CI) 0.40-0.64, P < 0.001 and HR = 0.64 (grade 1 to grade 0); 95% CI 0.52-0.80, P < 0.001]. In multivariate analysis, OS was significantly associated with skin toxicity. CONCLUSIONS A significant association was found between necitumumab-induced skin toxicity and efficacy. These results are consistent with the previously reported association between other EGFR inhibitors-induced skin toxicity and efficacy.
Collapse
MESH Headings
- Humans
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/pathology
- Lung Neoplasms/drug therapy
- Lung Neoplasms/pathology
- Male
- Female
- Middle Aged
- Aged
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antibodies, Monoclonal, Humanized/pharmacology
- Antibodies, Monoclonal, Humanized/adverse effects
- Randomized Controlled Trials as Topic
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Gemcitabine
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/pathology
- Deoxycytidine/analogs & derivatives
- Deoxycytidine/therapeutic use
- Cisplatin/therapeutic use
- Cisplatin/pharmacology
- Cisplatin/adverse effects
- Aged, 80 and over
Collapse
Affiliation(s)
- S Watanabe
- Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata
| | - H Yoshioka
- Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata.
| | - H Sakai
- Department of Thoracic Oncology, Ageo Central General Hospital, Ageo
| | - K Hotta
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama
| | - M Takenoyama
- Department of Thoracic Surgery, Matsuyama Red Cross Hospital, Matsuyama
| | - K Yamada
- Department of Respiratory Medicine, Shin Koga Hospital, Fukuoka
| | - S Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai
| | - Y Takiguchi
- Department of Medical Oncology, Chiba University Hospital, Chiba
| | - Y Hosomi
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo
| | - K Tomii
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe
| | - S Niho
- Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu
| | - M Nishio
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - T Kato
- Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama
| | - T Takahashi
- Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi
| | - H Ebi
- Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda-ku, Tokyo
| | - M Aono
- Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda-ku, Tokyo
| | - N Yamamoto
- Internal Medicine III, Wakayama Medical University, Wakayama
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
| |
Collapse
|
2
|
Kurimoto T, Goto T, Yasuda T, Yoshioka H. Histiocytic sarcoma of the palate: a case report. Int J Oral Maxillofac Surg 2023; 52:1225-1229. [PMID: 37643937 DOI: 10.1016/j.ijom.2023.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 07/18/2023] [Accepted: 08/03/2023] [Indexed: 08/31/2023]
Abstract
Histiocytic sarcoma is a malignant proliferation of cells that exhibit morphological and immunophenotypic features of mature histiocytes. Owing to its rarity, its clinical features and standard treatment have not yet been established. This report describes a case of histiocytic sarcoma of the palate that developed in a 76-year-old man, the first report of an intraoral histiocytic sarcoma. An extended resection was performed; however, establishing the excision line was extremely difficult because assessing the tumour boundary on imaging was challenging and the tumour underwent dynamic gross morphological changes following biopsy. Complete resection is required to obtain a favourable prognosis for high-grade tumours with indistinct borders. In this case, an intraoperative rapid examination with frozen section analysis was performed along the planned excision line to completely resect the tumours exhibiting such behaviour. At 28 months postoperatively, the patient demonstrated no recurrence or metastasis; however, he is under careful monitoring.
Collapse
Affiliation(s)
- T Kurimoto
- Department of Dentistry and Oral & Maxillofacial Surgery, Osaka Rosai Hospital, Sakai, Osaka, Japan.
| | - T Goto
- Department of Pathology, Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - T Yasuda
- Department of Dentistry and Oral & Maxillofacial Surgery, Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - H Yoshioka
- Department of Dentistry and Oral & Maxillofacial Surgery, Osaka Rosai Hospital, Sakai, Osaka, Japan
| |
Collapse
|
3
|
Yoshioka H, Hamagami K, Tomobe H. A Non-local Fokker-Planck Equation with Application to Probabilistic Evaluation of Sediment Replenishment Projects. Methodol Comput Appl Probab 2023. [DOI: 10.1007/s11009-023-10006-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
4
|
Kuyama S, Yoshioka H, Kaneda H, Kataoka Y, Miura S, Katakami N, Yamanaka Y, Tamiya A, Yamada T, Yokoyama T, Hara S, Tanaka H, Fujisaka Y, Nakamura A, Azuma K, Namba M, Hata A, Sawa K, Ishikawa H, Kurata T. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
5
|
Morita R, Hata A, Ota T, Sumi T, Yoshioka H, Osugi J, Fujisaka Y, Mitsui M, Morita S, Katakami N. EP08.02-133 Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Nakata M, Shimbo T, Kihara A, Sato C, Hori A, Yoshioka H, Yoshida K, Nihei K. Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer. Clin Oncol (R Coll Radiol) 2022; 34:e430-e436. [PMID: 35715341 DOI: 10.1016/j.clon.2022.05.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 05/01/2022] [Accepted: 05/23/2022] [Indexed: 11/18/2022]
Abstract
AIMS A novel bladder preservation therapy, the OMC (Osaka Medical College) regimen, which combines radiation therapy with balloon-occluded arterial infusion of anticancer agents, is a treatment option for patients with muscle-invasive bladder cancer (MIBC). We retrospectively analysed the effects of changes in radiation dose and irradiation field on treatment efficacy and adverse events.The purpose of this study is to use the results of this study to help determine a course of radiation therapy for bladder preservation therapy of cT2N0M0 MIBC. MATERIALS AND METHODS We examined 352 patients with clinical stage T2N0M0 (cT2N0M0) MIBC classified into the following groups based on the irradiation method: group A, the whole pelvis (50 Gy/25 fractions) + local bladder (10 Gy/5 fractions); group B, the small pelvis (50 Gy/25 fractions) + local bladder (10 Gy/5 fractions); group C, the whole pelvis (40 Gy/20 fractions) + local bladder (10 Gy/5 fractions). RESULTS The complete response rate, 3-year overall survival and progression-free survival rates in group A were 92.9%, 94.9% and 82.1%, respectively; in group B were 87.2%, 86.7% and 76.7%, respectively; and in group C were 95.2%, 92.6% and 71.1%, respectively. No significant differences between the groups were noted. The incidence of ≥grade 3 urinary tract and gastrointestinal toxicities were not significantly different among the groups (group A: 7.8%, 1.7%; B, 11.1%, 0%; C, 7.1%, 1.8%, respectively). The 3-year progression-free rates of the common iliac lymph node (CILN) region in patients who received whole-pelvis and small-pelvis irradiation were 99.0 and 89.0% (P < 0.01), respectively, with the latter group having significantly high lymph node recurrence in the CILN region. CONCLUSIONS Our findings showed that the optimal radiation therapy for patients with cT2N0M0 MIBC undergoing the OMC regimen is whole-pelvis irradiation including the CILN region, with a total dose of 50 Gy/25 fractions.
Collapse
Affiliation(s)
- M Nakata
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - T Shimbo
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
| | - A Kihara
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - C Sato
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - A Hori
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - H Yoshioka
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - K Yoshida
- Department of Radiology, Kansai Medical University Medical Center, Osaka, Japan
| | - K Nihei
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| |
Collapse
|
7
|
Miura S, Azuma K, Yoshioka H, Teraoka S, Ishii H, Koyama K, Kibata K, Ozawa Y, Tokito T, Koh Y, Shimokawa T, Kurata T, Yamamoto N, Tanaka H. MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Tedeschini T, Campara B, Grigoletto A, Bellini M, Salvalaio M, Matsuno Y, Suzuki A, Yoshioka H, Pasut G. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. J Control Release 2021; 337:431-447. [PMID: 34329685 DOI: 10.1016/j.jconrel.2021.07.041] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 07/21/2021] [Accepted: 07/23/2021] [Indexed: 01/12/2023]
Abstract
Antibody-drug conjugates (ADCs) are an established therapeutic entity in which potent cytotoxic drugs are conjugated to a monoclonal antibody. In parallel with the great emphasis put on novel site-specific bioconjugation technologies, future advancements in this field also rely on exploring novel linker-drug architectures that improve the efficacy and stability of ADCs. In this context, the use of hydrophilic linkers represents a valid strategy to mask or reduce the inherent hydrophobicity of the most used cytotoxic drugs and positively impact the physical stability and in vivo performance of ADCs. Here, we describe the use of linkers containing monodisperse poly(ethylene glycol) (PEG) moieties for the construction of highly-loaded lysine-conjugated ADCs. The studied ADCs differ in the positioning of PEG (linear or pendant), the bonding type with the antibody (amide or carbamate), and the drug-to-antibody ratio (DAR). These ADCs were first evaluated for their stability in solution under thermal stress, showing that both the drug-linker-polymer design and the nature of the antibody-linker bonding are of great importance for their physical and chemical stability. Amide-coupled ADCs bearing two pendant 12-unit poly(ethylene glycol) chains within the drug-linker structure were the best performing conjugates, distancing themselves from the ADCs obtained with a conventional linear 24-unit PEG oligomer or the linker of Kadcyla®. The pharmacokinetic profiles of amide-linked ADCs, with a linear or pendant configuration of the PEG, were tested in mice in comparison to Kadcyla®. Total antibody pharmacokinetics paralleled the trends in aggregation tendency, with slower clearance rates for the ADCs based on the pendant drug-linker format. The above-mentioned findings have provided important clues on the drug-linker design and revealed that the positioning and configuration of a PEG unit have to be carefully tuned to achieve ADCs with improved stability and pharmacokinetics.
Collapse
Affiliation(s)
- T Tedeschini
- University of Padova, Dept. Pharmaceutical Sciences, Via Marzolo 5, 35131 Padova, Italy
| | - B Campara
- University of Padova, Dept. Pharmaceutical Sciences, Via Marzolo 5, 35131 Padova, Italy
| | - A Grigoletto
- University of Padova, Dept. Pharmaceutical Sciences, Via Marzolo 5, 35131 Padova, Italy
| | - M Bellini
- University of Padova, Dept. Pharmaceutical Sciences, Via Marzolo 5, 35131 Padova, Italy
| | - M Salvalaio
- University of Padova, Dept. Pharmaceutical Sciences, Via Marzolo 5, 35131 Padova, Italy
| | - Y Matsuno
- NOF CORPORATION, DDS Research Laboratory, 3-3 Chidori-Cho, Kawasaki-Ku, Kawasaki, Kanagawa 210-0865, Japan
| | - A Suzuki
- NOF CORPORATION, DDS Research Laboratory, 3-3 Chidori-Cho, Kawasaki-Ku, Kawasaki, Kanagawa 210-0865, Japan
| | - H Yoshioka
- NOF CORPORATION, DDS Research Laboratory, 3-3 Chidori-Cho, Kawasaki-Ku, Kawasaki, Kanagawa 210-0865, Japan
| | - G Pasut
- University of Padova, Dept. Pharmaceutical Sciences, Via Marzolo 5, 35131 Padova, Italy.
| |
Collapse
|
9
|
Ito K, Morise M, Wakuda K, Hataji O, Shimokawaji T, Takahashi K, Furuya N, Takeyama Y, Goto Y, Abe T, Kato T, Ozone S, Ikeda S, Kogure Y, Yokoyama T, Kimura M, Yoshioka H, Murotani K, Kondo M, Saka H. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open 2021; 6:100115. [PMID: 33984681 PMCID: PMC8134659 DOI: 10.1016/j.esmoop.2021.100115] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 03/14/2021] [Accepted: 03/19/2021] [Indexed: 11/25/2022] Open
Abstract
Background FLAURA, the prospective trial of osimertinib as a first-line therapy compared with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), did not show superior survival benefit for osimertinib in either the subgroup of Asians or the subgroup with the L858R mutation. In addition, the superiority of osimertinib compared with second-generation EGFR-TKI is thus far unclear. Patients and methods We reviewed the clinical data of all consecutive patients who were treated with osimertinib or afatinib as first-line therapy between May 2016 and October 2019 from 15 institutions in Japan. We defined the groups based on first-line EGFR-TKI as the afatinib group and the osimertinib group. Outcomes included time to discontinuation of any EGFR-TKI (TD-TKI), overall survival (OS), and time to treatment failure, with propensity score analysis carried out as an exploratory analysis in the survival and subgroup analyses. Results A total of 554 patients were enrolled. Data on 326 patients in the osimertinib group, and 224 patients in the afatinib group were analyzed. TD-TKI adjusted by propensity score in the afatinib and osimertinib groups was 18.6 months (95% confidence interval 15.8 to 22.0) and 20.5 months (95% confidence interval 13.8 to not reached), respectively, without significant difference (P = 0.204). OS adjusted by propensity score favored the afatinib group with a significant difference (P = 0.018). Subgroup analysis with propensity score showed that patients with L858R and without brain metastasis had superior survival benefit with afatinib compared with osimertinib (P < 0.001). Conclusions TD-TKI in the afatinib group was not significantly prolonged compared with the osimertinib group in the practical data. In the exploratory analysis of patients with L858R-mutated non-small-cell lung cancer without brain metastasis, afatinib showed more benefit in OS over osimertinib. The large-scale practical data of 550 patients who were treated with osimertinib or afatinib as first-line therapy were analyzed. The superiority of osimertinib compared with afatinib could not be demonstrated in all populations. Osimertinib therapy showed effectiveness in patients with brain metastasis. Afatinib therapy showed potential benefit in patients with L858R mutation and without brain metastasis.
Collapse
Affiliation(s)
- K Ito
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
| | - M Morise
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
| | - K Wakuda
- Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou-gun, Shizuoka, Japan
| | - O Hataji
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan
| | - T Shimokawaji
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
| | - K Takahashi
- Department of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Aichi, Japan
| | - N Furuya
- Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - Y Takeyama
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
| | - Y Goto
- Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - T Abe
- Department of Respiratory Medicine, Ogaki Municipal Hospital, Ogaki, Gifu, Japan
| | - T Kato
- Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - S Ozone
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - S Ikeda
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan
| | - Y Kogure
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
| | - T Yokoyama
- Department of Respiratory Medicine, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan
| | - M Kimura
- Department of Respiratory Medicine, Toyota Memorial Hospital, Toyota, Aichi, Japan
| | - H Yoshioka
- Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan
| | - K Murotani
- Biostatistics Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Kondo
- Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - H Saka
- Department of Respiratory Medicine, Matsunami General Hospital, Kasamatsu, Gifu, Japan
| |
Collapse
|
10
|
Nakamura A, Yoneshima Y, Morita S, Ando M, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. OA03.05 Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Saito R, Tsubata Y, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Watanabe M, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Kobayashi K, Morita S, Isobe T. P76.79 Osimertinib in Poor PS Patients with T790M-Positive Advanced NSCLC after Progression of EGFR TKI Treatments (NEJ032B). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Yoshioka H, Tsujimura M. Stochastic control of single-species population dynamics model subject to jump ambiguity. J Biol Dyn 2020; 14:696-729. [PMID: 32845218 DOI: 10.1080/17513758.2020.1811408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 08/10/2020] [Indexed: 06/11/2023]
Abstract
A logistic type stochastic control model for cost-effective single-species population management subject to an ambiguous jump intensity is presented based on the modern multiplier-robust formulation. The Hamilton-Jacobi-Bellman-Isaacs (HJBI) equation for finding the optimal control is then derived. Mathematical analysis of the HJBI equation from the viewpoint of viscosity solutions is carried out with an emphasis on the non-linear and non-local term, which is a key term arising due to the jump ambiguity. We show that this term can be efficiently handled in the framework of viscosity solutions by utilizing its monotonicity property. A numerical scheme to discretize the HJBI equation is presented as well. Our model is finally applied to management of algae population in river environment. Optimal management policies ranging from the short-term to long-term viewpoints are numerically investigated.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- School of Natural Science and Technology, Shimane University, Matsue, Japan
| | - Motoh Tsujimura
- Graduate School of Commerce, Doshisha University, Kyoto, Japan
| |
Collapse
|
13
|
Yoshioka H, Mori M, Katakami N, Yokoyama T, Kaneda H, Hirano K, Kumagai T, Huang CL. 405P Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
14
|
Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Satouchi M, Yamamoto N, Nakagawa K. LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2288] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
15
|
Yoshioka H. Two-species competing population dynamics with the population-dependent environmental capacities under random disturbance. Theory Biosci 2020; 139:279-297. [PMID: 32780209 DOI: 10.1007/s12064-020-00321-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 08/01/2020] [Indexed: 10/23/2022]
Abstract
We propose and analyze a stochastic competing two-species population dynamics model subject to jump and continuous correlated noises. Competing benthic algae population dynamics in river environment, which is an important engineering problem, motivates this new model. The model is a system of stochastic differential equations having a characteristic that the two populations are competing with each other through the environmental capacities; an increase in one population decreases the other's environmental capacity. Unique existence of the uniformly bounded strong solution is proven, and attractors of the solutions are identified depending on the parameter values. The Kolmogorov's backward equation associated with the population dynamics is formulated and its unique solvability in a Banach space with a weighted norm is discussed. A novel uncertain correlation case is also analyzed in the framework of viscosity solutions. Numerical computation results using a finite difference scheme and a Monte-Carlo method are presented to deeper analyze the model. Our analysis results can be utilized for establishment of a foundation for modeling, analysis and control of the competing population dynamics.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- Graduate School of Natural Science and Technology, Shimane University, Nishikawatsu-cho 1060, Matsue, 690-8504, Japan.
| |
Collapse
|
16
|
Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol 2019; 30:1978-1984. [PMID: 31553438 DOI: 10.1093/annonc/mdz399] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. PATIENTS AND METHODS Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. RESULTS OS events in the G group and CD group were 68 (79.1%) out of 86 and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95% confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. CONCLUSION G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease.This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.
Collapse
Affiliation(s)
- H Yoshioka
- Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata
| | - M Shimokawa
- Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube
| | - T Seto
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - S Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto
| | - Y Yatabe
- Department of Pathology and Molecular Genetics, Aichi Cancer Center Hospital, Nagoya
| | - I Okamoto
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka
| | - J Tsurutani
- Advanced Cancer Translational Research Institute, Showa University, Tokyo
| | - M Satouchi
- Department of Thoracic Oncology, Hyogo Cancer Center, Akashi
| | - T Hirashima
- Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino
| | - S Atagi
- Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai
| | - K Shibata
- Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka
| | - H Saito
- Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki
| | - S Toyooka
- Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
| | - N Yamamoto
- Internal Medicine III, Wakayama Medical University Hospital, Wakayama
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Hospital, Osaka-Sayama
| | - T Mitsudomi
- Division of Thoracic Surgery, Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan.
| |
Collapse
|
17
|
Yoshioka H, Tanaka T, Aranishi F, Izumi T, Fujihara M. Stochastic optimal switching model for migrating population dynamics. J Biol Dyn 2019; 13:706-732. [PMID: 31701818 DOI: 10.1080/17513758.2019.1685134] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 10/18/2019] [Indexed: 06/10/2023]
Abstract
An optimal switching control formalism combined with the stochastic dynamic programming is, for the first time, applied to modelling life cycle of migrating population dynamics with non-overlapping generations. The migration behaviour between habitats is efficiently described as impulsive switching based on stochastic differential equations, which is a new standpoint for modelling the biological phenomenon. The population dynamics is assumed to occur so that the reproductive success is maximized under an expectation. Finding the optimal migration strategy ultimately reduces to solving an optimality equation of the quasi-variational type. We show an effective linkage between our optimality equation and the basic reproduction number. Our model is applied to numerical computation of optimal migration strategy and basic reproduction number of an amphidromous fish Plecoglossus altivelis altivelis in Japan as a target species.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- Graduate School of Natural Science and Technology, Shimane University, Matsue, Japan
- Fisheries Ecosystem Project Center, Shimane University, Matsue, Japan
| | - Tomomi Tanaka
- Fisheries Ecosystem Project Center, Shimane University, Matsue, Japan
| | - Futoshi Aranishi
- Graduate School of Natural Science and Technology, Shimane University, Matsue, Japan
- Fisheries Ecosystem Project Center, Shimane University, Matsue, Japan
| | - Tomoki Izumi
- Graduate School of Agriculture, Ehime University, Matsuyama, Japan
| | | |
Collapse
|
18
|
Yoshioka H. A simplified stochastic optimization model for logistic dynamics with control-dependent carrying capacity. J Biol Dyn 2019; 13:148-176. [PMID: 30727850 DOI: 10.1080/17513758.2019.1576927] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/26/2018] [Accepted: 01/22/2019] [Indexed: 06/09/2023]
Abstract
A simplified stochastic control model for optimization of logistic dynamics with the control-dependent carrying capacity, which is motivated by a recent algae population management problem in the river environment, is presented. Solving the optimization problem reduces to finding a solution to a non-local first-order differential equation called tt-Jacobi-Bellman (HJB) equation. It is shown that the HJB equation has a unique viscosity solution and that the solution can be approximated with a finite difference scheme. Asymptotic estimates of the solution and the optimal control are derived and compared with numerical solutions. Finally, parameter dependence of the optimal control is examined numerically with implications to river environmental management.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- a Graduate School of Natural Science and Technology, Shimane University , Matsue, Nishikawatsu-cho , Japan
| |
Collapse
|
19
|
Kibata K, Izuno H, Nakahama K, Yamanaka Y, Kaneda T, Yoshioka H, Kurata T, Nomura S. Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Ishida T, Tomii K, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim Y, Yoshimura K, Hirai T. Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I. MA13.06 Ph3 Study of Maintenance Therapy with S-1 vs BSC After Induction Therapy with Carboplatin + S-1 for Advanced Squamous Cell Lung Cancer (WJOG7512L). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Kogure Y, Niwa T, Yoshioka H, Saka H, Hata A, Katakami N, Ozawa Y, Matsuo N, Hoshino T, Wakuda K, Kenmotsu H, Takahashi T, Nosaki K, Takenoyama M, Tajima M, Takahashi K, Ando M, Yamamoto N. P1.01-04 A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Abstract
A stochastic differential game model for animal migration between two habitats under uncertain environment, a new population dynamics model, is formulated. Its novelty is the use of an impulse control formalism to naturally describe migrations with different timings and magnitudes that the conventional models could not handle. Uncertainty of the environment that the population faces with is formulated in the context of the multiplier robust control. The optimal migration strategy to give the maximized minimal profit is found through a Hamilton-Jacobi-Bellman quasi-variational inequality (HJBQVI). A key message from HJBQVI is that its free boundary determines the optimal migration strategy. Solving the HJBQVI is carried out with a specialized stable and convergent finite difference scheme. This paper theoretically suggests that the sub-additivity of the performance index, the index to be optimized through the migration, critically affects the resulting strategy. The computational results with the established scheme are consistent with the theoretical predictions and support importance of the sub-additivity property. Social interaction to reduce the net mortality rate is also quantified, suggesting a linkage between the present and existing population dynamics models.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- Faculty of Life and Environmental Science, Shimane University, Nishikawatsu-cho, Matsue, 1060, Japan.
| |
Collapse
|
24
|
Yoshioka H, Shimbo T, Tanaka Y, Hori A, Nakata M, Yoshikawa N, Yoshida K, Uesugi Y, Yamamoto K. EP-1588 The preliminary result of combination of chemoradiotherapy and arterial infusion for bladder cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32008-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
25
|
Yoshioka H, Yaegashi Y. Stochastic differential game for management of non-renewable fishery resource under model ambiguity. J Biol Dyn 2018; 12:817-845. [PMID: 30325271 DOI: 10.1080/17513758.2018.1528394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Accepted: 09/19/2018] [Indexed: 06/08/2023]
Abstract
A new bio-economic model for managing population of non-renewable inland fishery resource in uncertain environment is presented. Population dynamics of the resource is described with stochastic differential equations (SDEs) having ambiguous growth and mortality rates. The performance index to be maximized by the manager of the resource while minimized by nature is presented in the context of differential game theory. The dynamic programming principle leads to a Hamilton-Jacobi-Bellman-Isaacs (HJBI) equation that governs the optimal resource management strategy under the ambiguity. The main contribution of this paper is a series of theoretical analysis on the reduced HJBI equation for non-renewable fishery resources in a broad sense, indicating that the ambiguity critically affects the resulting optimal controls. Practical implications of the theoretical analysis results are also presented focusing on artificially hatched Plecoglossus altivelis (Ayu), an important inland fishery resource in Japan.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- a Faculty of Life and Environmental Science , Shimane University , Matsue , Japan
| | - Yuta Yaegashi
- b Graduate School of Agriculture , Kyoto University , Kyoto , Japan
- c Japan Society for the Promotion of Science , Tokyo , Japan
| |
Collapse
|
26
|
Yoshioka H, Yaegashi Y. Singular stochastic control model for algae growth management in dam downstream. J Biol Dyn 2018; 12:242-270. [PMID: 29461937 DOI: 10.1080/17513758.2018.1436197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 01/25/2018] [Indexed: 06/08/2023]
Abstract
A stochastic control model for finding an ecologically sound, fit-for-purpose dam operation policy to suppress bloom of attached algae in its downstream is presented. A singular exactly solvable and a more realistic regular-singular cases are analysed in terms of a Hamilton-Jacobi-Bellman equation. Regularity and consistency of the value function are analysed and its classical verification theorem is established. Practical implications of the mathematical analysis results are discussed focusing on parameter dependence of the optimal controls. An asymptotic analysis with a numerical computation reveals solution behaviour of the Hamilton-Jacobi-Bellman equation near the origin, namely at the early stage of algae growth.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- a Faculty of Life and Environmental Science , Shimane University , Matsue , Shimane , Japan
| | - Yuta Yaegashi
- b Graduate School of Agriculture , Kyoto University , Sakyo-ku , Kyoto , Japan
- c Japan Society for the Promotion of Science , Tokyo , Japan
| |
Collapse
|
27
|
Harada T, Udagawa H, Sugiyama E, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Niimi A, Kida H, Satouchi M, Inoue A, Urata Y, Yamane Y, Yoh K, Yoshioka H, Yamanaka T, Goto K. P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.589] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Yaegashi Y, Yoshioka H, Unami K, Fujihara M. A singular stochastic control model for sustainable population management of the fish-eating waterfowl Phalacrocorax carbo. J Environ Manage 2018; 219:18-27. [PMID: 29723745 DOI: 10.1016/j.jenvman.2018.04.099] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 04/13/2018] [Accepted: 04/23/2018] [Indexed: 06/08/2023]
Abstract
Using a tractable singular stochastic control model, this study seeks a sustainable population management policy for the fish-eating waterfowl Phalacrocorax carbo (Great Cormorant), a major predator of riverine fish in Japan. The bird population dynamics around a habitat lake are described by a stochastic differential equation with a singular control variable representing human interventions to suppress the predation. The optimal population management policy maximizes a performance index that covers the cost of countermeasures, the loss of riverine fish, and the ecosystem services provided by the bird. The dynamic programming principle obtains an exactly-solvable variational inequality that governs a sustainable, threshold-type optimal management policy. In this policy, countermeasures are taken when the population reaches a certain level. The model is applied to management of P. carbo population around Lake Biwa, Japan, where predation of riverine fish is the most severe in the country. The current management policy around the lake is analyzed and verified in the context of the proposed model, focusing on the population-control threshold and the average population reduction per unit time.
Collapse
Affiliation(s)
- Yuta Yaegashi
- Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8502, Japan; Research Fellow of Japan Society for the Promotion of Science, Japan.
| | - Hidekazu Yoshioka
- Faculty of Life and Environmental Science, Shimane University, Nishikawatsu-cho 1060, Matsue City, Shimane Prefecture, 690-8504, Japan.
| | - Koichi Unami
- Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8502, Japan.
| | - Masayuki Fujihara
- Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8502, Japan.
| |
Collapse
|
29
|
Kataoka Y, Ebi N, Fujimoto D, Hara S, Hirano K, Narabayashi T, Tanaka T, Tomii K, Yoshioka H. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study. Ann Oncol 2018; 28:1402. [PMID: 28368440 DOI: 10.1093/annonc/mdx114] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Y Kataoka
- Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki
| | - N Ebi
- Department of Respiratory Medicine, Iizuka Hospital, Iizuka
| | - D Fujimoto
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe
| | - S Hara
- Respiratory Division, Department of Internal Medicine, Itami City Hospital, Itami
| | - K Hirano
- Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki
| | - T Narabayashi
- Department of Internal Medicine, JCHO Osaka Hospital, Osaka
| | - T Tanaka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan
| | - K Tomii
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe
| | - H Yoshioka
- Department of Internal Medicine, JCHO Osaka Hospital, Osaka
| |
Collapse
|
30
|
Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 2018; 28:1532-1539. [PMID: 28407039 DOI: 10.1093/annonc/mdx183] [Citation(s) in RCA: 223] [Impact Index Per Article: 37.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Indexed: 12/22/2022] Open
Abstract
Background The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR. Patients and methods We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab after disease progression during EGFR-TKI treatment (cohort A). Programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocyte (TIL) density in tumor specimens obtained after acquisition of EGFR-TKI resistance were determined by immunohistochemistry. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. The relation of T790M status to PD-L1 expression or TIL density was also examined in an independent cohort of 60 patients (cohort B). Results In cohort A, median progression-free survival (PFS) was 2.1 and 1.3 months for T790M-negative and T790M-positive patients, respectively (P = 0.099; hazard ratio of 0.48 with a 95% confidence interval of 0.20-1.24). Median PFS was 2.1 and 1.3 months for patients with a PD-L1 expression level of ≥1% or <1%, respectively (P = 0.084; hazard ratio of 0.37, 95% confidence interval of 0.10-1.21). PFS tended to increase as the PD-L1 expression level increased with cutoff values of ≥10% and ≥50%. The proportion of tumors with a PD-L1 level of ≥10% or ≥50% was higher among T790M-negative patients than among T790M-positive patients of both cohorts A and B. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. Conclusion T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, than are T790M-positive patients.
Collapse
Affiliation(s)
- K Haratani
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - H Hayashi
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - T Tanaka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki
| | - H Kaneda
- Department of Medical Oncology, Kishiwada City Hospital, Kishiwada
| | - Y Togashi
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama.,Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Hayashi
- Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki
| | - S Tomida
- Department of Biobank, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama
| | - Y Chiba
- Clinical Research Center, Kindai University Hospital, Osaka-Sayama
| | - K Yonesaka
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - Y Nonagase
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - T Takahama
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - J Tanizaki
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Tanaka
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - T Yoshida
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Tanimura
- Department of Respiratory Medicine, Kishiwada City Hospital, Kishiwada
| | - M Takeda
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - H Yoshioka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki
| | - T Ishida
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki
| | - T Mitsudomi
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| |
Collapse
|
31
|
Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol 2017; 28:285-291. [PMID: 28426104 DOI: 10.1093/annonc/mdw621] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a standard treatment for NSCLC, have been reported. Patients and methods We conducted a randomized phase III trial of Japanese NSCLC patients after one or two chemotherapy regimens. Patients were randomized to amrubicin (35 mg/m2 on days 1-3 every 3 weeks) or docetaxel (60 mg/m2 on day 1 every 3 weeks). Outcomes included progression-free survival, overall survival, tumor responses, and safety. Results Between October 2010 and June 2012, 202 patients were enrolled across 32 institutions. Median progression-free survival (3.6 versus 3.0 months; P = 0.54) and overall survival (14.6 versus 13.5 months; P = 0.86) were comparable in the amrubicin and docetaxel groups, respectively. The overall response rate was 14.4% (14/97) and 19.6% (19/97) in the amrubicin and docetaxel groups, respectively (P = 0.45). The disease control rate was 55.7% in both groups. Adverse events occurred in all patients, and included grade ≥3 neutropenia occurred in 82.7% and 78.8% of patients in the amrubicin and docetaxel groups, respectively, grade ≥3 leukopenia occurred in 63.3% and 70.7%, and grade ≥3 febrile neutropenia occurred in 13.3% and 18.2% of patients in the amrubicin and docetaxel groups, respectively. Of eight cardiac-related events in the amrubicin group, three were considered related to amrubicin and resolved without treatment discontinuation. Conclusions This was the first phase III study to compare amrubicin and docetaxel in patients with pretreated NSCLC. Amrubicin did not significantly improve the primary endpoint of PFS compared with docetaxel. Clinical trial registration NCT01207011 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- H Yoshioka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama
| | - N Katakami
- Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Hyogo
| | - H Okamoto
- Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Kanagawa
| | - Y Iwamoto
- Department of Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima
| | - T Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka
| | - T Takahashi
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka
| | - N Sunaga
- Department of Medicine and Molecular Science, Gunma University School of Medicine, Gunma
| | - S Kudoh
- Department of Respiratory Medicine, Osaka City University Hospital, Osaka
| | - K Chikamori
- Department of Respiratory Medicine, National Hospital Organization Yamaguchi-Ube Medical Center, Yamaguchi
| | - M Harada
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo
| | - H Tanaka
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata
| | - H Saito
- Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Aichi
| | - H Saka
- Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi
| | - K Takeda
- Department of Medical Oncology, Osaka City General Hospital, Osaka
| | - N Nogami
- Department of Respiratory Medicine, National Hospital Organization Shikoku Cancer Center, Ehime
| | - N Masuda
- Department of Respiratory Medicine, Kitasato University Hospital, Kanagawa
| | - T Harada
- Center of Respiratory Disease, Japan Community Health Care Organization Hokkaido Hospital, Sapporo
| | - H Kitagawa
- Drug Development Division, Sumitomo Dainippon Pharma. Co, Ltd, Tokyo
| | - H Horio
- Drug Development Division, Sumitomo Dainippon Pharma. Co, Ltd, Tokyo
| | - T Yamanaka
- Department of Biostatistics and Epidemiology, Graduate School of Medicine, Yokohama City University, Kanagawa
| | - M Fukuoka
- Medical Oncology, Izumi Municipal Hospital, Osaka
| | - N Yamamoto
- Third Department of Internal Medicine, Wakayama Medical University Hospital, Wakayama
| | - K Nakagawa
- Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, Osaka, Japan
| |
Collapse
|
32
|
Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H. P1.07-004 Predictive Biomarkers of Response to Nivolumab in Non–Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Kimura T, Kawaguchi T, Kudoh S, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Tanaka H, Yano S, Nakamura S, Yamamoto N, Nakanishi Y, Nakagawa K. P2.03-008 Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Fujimoto D, Yokoyama T, Yoshioka H, Demura Y, Hirano K, Kawai T, Kagami R, Ishida T, Tomii K, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim Y, Yoshimura K, Hirai T. A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Nishio M, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Takeuchi K, Inamura S, Kuriki H, Shimada T, Tamura T. OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Fujimoto D, Yoshioka H, Kataoka Y, Kim Y, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang M, Sakai N, Fukui M, Nakaji H, Hirai T. P2.07-024 Real-World Data of Nivolumab for Previously Treated Non-Small Cell Lung Cancer Patients in Japan: A Multicenter Retrospective Cohort Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Ikeda S, Yoshioka H, Ikeo S, Morita M, Sone N, Niwa T, Nishiyama A, Yokoyama T, Sekine A, Ogura T, Ishida T. P2.01-001 Serum Albumin Level Predicts the Survival Benefit of Chemotherapy in Elderly Advanced NSCLC Patients with Poor Performance Status. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Kudo K, Kuyama S, Harada D, Kozuki T, Bessho A, Hotta K, Yoshioka H, Gemba K, Takigawa N, Oze I, Kiura K. P2.01-034 Phase I/II Trial of Weekly Nab-Paclitaxel as 2nd or 3rd Line Treatment in NSCLC Without Driver Mutations. (OLCSG1303). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Kibata K, Yokoi T, Yoshioka H, Kurata T, Nomura S. Efficacy and toxicity of nivolumab in real-world; including nivolumab rechallenge. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Nozaki T, Rafijah G, Yang L, Ueno T, Horiuchi S, Hitt D, Yoshioka H. High-resolution 3 T MRI of traumatic and degenerative triangular fibrocartilage complex (TFCC) abnormalities using Palmer and Outerbridge classifications. Clin Radiol 2017; 72:904.e1-904.e10. [DOI: 10.1016/j.crad.2017.04.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 04/05/2017] [Accepted: 04/11/2017] [Indexed: 11/16/2022]
|
41
|
Tanaka T, Yoshioka H, Bessho A, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Fujimoto N, Genba K, Ueda Y, Inoue M, Murakami T, Kuyama S, Kawai H, Fujitaka K, Inoue K, Takata M, Yanai H, Kiura K. A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Ninomiya T, Hotta K, Ohashi K, Kubo T, Harada D, Kozuki T, Nogami N, Oze I, Hosokawa S, Bessho A, Yoshioka H, Kudo K, Kuyama S, Harita S, Takata I, Fujimoto N, Moritaka T, Ichikawa H, Takigawa N, Kiura K. Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Abstract
A simple game-theoretic model for upstream fish migration, which is a key element in life history of diadromous fishes, is proposed. Foundation of the model is a minimization problem on the cost of migration with the swimming speed and school size as the variables to be simultaneously optimized. Finding the optimizer ultimately reduces to solving a self-consistency equation without explicit solutions. Mathematical analytical results lead to the sufficient condition that the self-consistency equation has a unique solution, which turns out to be identified with the condition where the unique optimizer exists. Behavior of the optimizer is analyzed both mathematically and numerically to show its biophysical and ecological consequences. The analytical results demonstrate reasonable agreement between the present mathematical model and the theoretical and experimental results of upstream migration of fish schools reported in the past research.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- Faculty of Life and Environmental Science, Shimane University, Nishikawatsu-cho 1060, Matsue, Shimane, 690-8504, Japan.
| |
Collapse
|
44
|
Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Masui K, Komori T, Shimbo T, Yoshikawa N, Yoshioka H, Uesugi Y, Hamada T, Nakata M, Matsutani H, Ueda M, Tsujimoto Y, Tanaka E, Narumi Y. PO-0937: HDR image-guided interstitial brachytherapy for postoperative local recurrent uterine cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31374-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
45
|
Shimbo T, Yoshida K, Yoshikawa N, Yoshioka H, Nakata M, Narumi Y, Komori T, Matsutani H, Hamada T, Uesugi Y. EP-1162: Non surgical breast conserving treatment using a new radiosensitizer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31598-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Yoshioka H. Mathematical analysis and validation of an exactly solvable model for upstream migration of fish schools in one-dimensional rivers. Math Biosci 2016; 281:139-148. [PMID: 27693303 DOI: 10.1016/j.mbs.2016.09.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 09/16/2016] [Accepted: 09/20/2016] [Indexed: 11/15/2022]
Abstract
Upstream migration of fish schools in 1-D rivers as an optimal control problem is formulated where their swimming velocity and the horizontal oblateness are taken as control variables. The objective function to be maximized through a migration process consists of the biological and ecological profit to be gained at the upstream-end of a river, energetic cost of swimming against the flow, and conceptual cost of forming a school. Under simplified conditions where the flow is uniform in both space and time and the profit to be gained at the goal of migration is sufficiently large, the optimal control variables are determined from a system of algebraic equations that can be solved in a cascading manner. Mathematical analysis of the system reveals that the optimal controls are uniquely found and the model is exactly solvable under certain conditions on the functions and parameters, which turn out to be realistic and actually satisfied in experimental fish migration. Identification results of the functional shapes of the functions and the parameters with experimentally observed data of swimming schools of Plecoglossus altivelis (Ayu) validate the present mathematical model from both qualitative and quantitative viewpoints. The present model thus turns out to be consistent with the reality, showing its potential applicability to assessing fish migration in applications.
Collapse
Affiliation(s)
- Hidekazu Yoshioka
- Faculty of Life and Environmental Science, Shimane University, Nishikawatsu-cho 1060, Matsue, Shimane 690-8504, Japan.
| |
Collapse
|
47
|
Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.59] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Kato T, Takahashi T, Yoshioka H, Nakagawa K, Maemondo M, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Noguchi K, Shimamoto T, Nishio M. KEYNOTE-025: Phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non-small cell lung cancer (NSCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.21] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Niitsu M, Hirohata H, Yoshioka H, Anno I, Campeau NG, Itai Y. Magnetization Transfer Contrast on Gradient Echo MR Imaging of the Temporomandibular Joint. Acta Radiol 2016. [DOI: 10.1177/028418519503600317] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Thirty-nine temporomandibular joints (TMJ) from 20 patients with suspected internal derangements were imaged by a 1.5 T MR imager. The on-resonance binomial magnetization transfer contrast (MTC) pulse was applied to gradient echo images with a dual receiver coil (9 s/section). With the use of an opening device, a series of sequential images were obtained at increments of mouth opening and closing. The tissue signal intensities with (Ms) and without (Mo) MTC were measured and subjective image analysis was performed. Compared with the standard images, MTC technique provided selective signal suppression of disks. The average of Ms/Mo ratio of the disks (0.56) was lower than that of the retrodiskal pad (0.79) and of the effusion (0.89). With MTC technique, fluid conspicuity was superior to standard image. However, no significant superiority was found in disk definition subjectively.
Collapse
|
50
|
Yoshioka H, Nakagawa K, Shindou H, Ono Y, Kawakami A, Mabuchi N, Arita S, Fujii K, Hamada T, Ishida O, Miyakoshi K, Uto T. MR Imaging of the Liver before and after Transcatheter Hepatic Chemo-Embolization for Hepatocellular Carcinoma. Acta Radiol 2016. [DOI: 10.1177/028418519003100112] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Transcatheter chemo-embolization (TCE) in hepatocellular carcinoma (HCC) was performed in 38 patients. The patients were examined by MR imaging before TCE as well as one week and 4 to 5 weeks after TCE. The tumor signal intensity in T2 weighted images increased in 13 cases and decreased in 19 cases after TCE. Increased intensity seemed to reflect intra-tumoral hemorrhage or liquefaction accompanying tumor necrosis. Decreased intensity seemed to reflect coagulation necrosis. In 9 of 18 cases followed over a 2-month period the signal intensity had decreased in both T1 and T2 weighted images. In these patients the tumor showed no recurrence at angiography and the decreased signal seemed to reflect the completion of coagulation necrosis. A hyper- and/or hypointense rim around the tumor appeared in 22 cases. These changes were thought to be perifocal edema or granulation tissue around the tumor. MR imaging was useful in evaluating the necrotic process of the tumor after TCE.
Collapse
|